Gene therapy for sickle cell disease: An updateSelami Demirci, John F. Tisdale, Naoya Uchida|Cytotherapy|2018Cited by 114
Hematopoietic stem cells from pluripotent stem cells: Clinical potential, challenges, and future perspectivesSelami Demirci, John F. Tisdale, Alexis Leonard|Stem Cells Translational Medicine|2020Cited by 82
Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recoveryAlexis Leonard, John F. Tisdale, Juan J. Haro‐Mora et al.|British Journal of Haematology|2019Cited by 75
BCL11A enhancer–edited hematopoietic stem cells persist in rhesus monkeys without toxicitySelami Demirci, John F. Tisdale, Jing Zeng et al.|Journal of Clinical Investigation|2020Cited by 67
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and ChallengesSelami Demirci, John F. Tisdale, Alexis Leonard et al.|Advances in experimental medicine and biology|2019Cited by 62